World Health Organization, 2018
The objective of these guidelines from the World Health Organization (WHO) is to provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings.
The guidelines update the WHO Package of Essential Non-communicable Disease Interventions (WHO PEN) for primary care in low-resources settings recommendations for managing hyperglycaemia, reviewing several newer oral agents: dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors) and thiazolidinediones (TZDs). The guidelines also present new recommendations on the selection of type of insulin for adults with type 1 diabetes and in adults with type 2 diabetes.
Related to point-of-care testing, the guide provides useful information related to patient preferences for reducing numbers of injections and resource requirements for different medicines related to increased needles and self-monitoring, for example.
The full publication can be accessed here.
COL-08890 10/2021
© 2024 애보트. 판권 소유. 참조된 모든 상표는 Abbott 그룹 회사 또는 해당 소유자의 상표입니다.